Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$49.99 ▼ -1.43
(-2.78%)
MKT CAP: $4.83B • VOL: 1.03M
52W L $44 52W H $63
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$42
MEDIAN
$56
MEAN
$57
HIGH
$68
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE CRSP TAPE
CRSP // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $60.49 | $57.49 | 2025-02-14 | $45.49 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $62.99 | $58.99 | 2025-02-06 | $46.99 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $56.99 | $54.99 | 2025-01-29 | $47.99 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $50.99 | — | 2025-01-17 | $48.99 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $43.99 | $47.49 | 2025-01-09 | $44.49 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $59.49 | $51.99 | 2024-12-18 | $43.49 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $48.49 | $50.49 | 2024-12-04 | $46.49 | -4.3% | 48% | C |